DE69333412D1 - Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie - Google Patents

Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie

Info

Publication number
DE69333412D1
DE69333412D1 DE69333412T DE69333412T DE69333412D1 DE 69333412 D1 DE69333412 D1 DE 69333412D1 DE 69333412 T DE69333412 T DE 69333412T DE 69333412 T DE69333412 T DE 69333412T DE 69333412 D1 DE69333412 D1 DE 69333412D1
Authority
DE
Germany
Prior art keywords
kokains
cocoin
cataltic
analoga
des
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69333412T
Other languages
English (en)
Inventor
W Landry
Kang Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25339390&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69333412(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Application granted granted Critical
Publication of DE69333412D1 publication Critical patent/DE69333412D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657172—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and one oxygen atom being part of a (thio)phosphinic acid ester: (X = O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69333412T 1992-04-03 1993-04-02 Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie Expired - Lifetime DE69333412D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/862,801 US5463028A (en) 1992-04-03 1992-04-03 Reagents for generating a polyclonal hydrolytic antibody response against cocaine and the monoclonal hydrolytic antibodies against cocaine derived through these reagents
PCT/US1993/003163 WO1993020076A1 (en) 1992-04-03 1993-04-02 Catalytic antibodies against cocaine and methods of using and producing same

Publications (1)

Publication Number Publication Date
DE69333412D1 true DE69333412D1 (de) 2004-03-11

Family

ID=25339390

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333412T Expired - Lifetime DE69333412D1 (de) 1992-04-03 1993-04-02 Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie

Country Status (8)

Country Link
US (5) US5463028A (de)
EP (1) EP0642507B1 (de)
JP (1) JPH07508712A (de)
AT (1) ATE258933T1 (de)
AU (1) AU678161B2 (de)
CA (1) CA2132982C (de)
DE (1) DE69333412D1 (de)
WO (1) WO1993020076A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463028A (en) 1992-04-03 1995-10-31 The Trustees Of Columbia University In The City Of New York Reagents for generating a polyclonal hydrolytic antibody response against cocaine and the monoclonal hydrolytic antibodies against cocaine derived through these reagents
US5730985A (en) * 1994-06-13 1998-03-24 Governing Council Of The University Of Toronto Immunogens for the production of cocaine-hydrolyzing catalytic antibodies
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
EP0854934A4 (de) * 1995-08-18 2000-09-06 Donald W Landry Nachweis von organischen verbindungen regulation von durch antikörper katalysierten reaktionen
AU719289B2 (en) * 1995-12-14 2000-05-04 Scripps Research Institute, The Anti-cocaine vaccine
US5948658A (en) * 1996-06-25 1999-09-07 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody
AU2002226055A1 (en) * 2000-12-07 2002-06-18 The Scripps Research Institute Cocaine haptens
US20030073608A1 (en) * 2001-04-10 2003-04-17 Woolf Nancy J. Process for treating disease
EP1578754A4 (de) * 2002-10-30 2006-07-19 Makscientific Llc Ringsubstituiertephospholipide mit wirkung gegen protozoen
US8318156B2 (en) 2006-07-10 2012-11-27 The Trustees Of Columbia University In The City Of New York Anti-cocaine compositions and treatment
US8637009B2 (en) 2007-07-10 2014-01-28 The Trustees Of Columbia University In The City Of New York Thermostabilization of proteins
WO2011050158A1 (en) * 2009-10-22 2011-04-28 The Trustees Of Columbia University In The City Of New York Anti-drug vaccines
US8859098B2 (en) * 2012-05-18 2014-10-14 Lord Corporation Acrylic adhesion promoters
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203802A (en) * 1971-05-14 1980-05-20 Syva Company Inhibitable enzyme amplification assay
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3884898A (en) 1972-08-18 1975-05-20 Syva Co Normorphine derivatives bonded to proteins
US3975237A (en) 1972-11-06 1976-08-17 Syva Company Compounds for enzyme amplification assay - - ecgonine analogs
US4045420A (en) 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US4197237A (en) 1973-06-01 1980-04-08 Syva Company Antibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereof
US3888866A (en) 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US3917582A (en) * 1973-06-13 1975-11-04 Syva Corp Isothiocyanate and thiourea derivatives of benzoyl ecgonine conjugated to polypeptides
US4220722A (en) 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4235864A (en) 1978-04-10 1980-11-25 Research Corporation Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites
US4714676A (en) 1982-09-16 1987-12-22 Owens-Illinois Glass Container Inc. Protein modification to provide enzyme activity
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4650771A (en) 1983-11-04 1987-03-17 Miles Laboratories, Inc. Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
US5037750A (en) * 1984-11-27 1991-08-06 Igen, Inc. Method for producing antibodies which catalyze chemical reactions
JP2540508B2 (ja) * 1983-11-29 1996-10-02 イージエン・インコーポレイテッド 化学反応を触媒する方法
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4659567A (en) * 1984-09-07 1987-04-21 Scripps Clinic & Research Foundation Molecules with antibody combining sites that bind to hydrolytic transition states
US5030717A (en) * 1986-09-17 1991-07-09 Scripps Clinic And Research Foundation Antibodies which catalyze hydrolysis of ester bonds
US5202270A (en) 1986-05-15 1993-04-13 Abbott Laboratories Cocaine and cocaine metabolites assay tracers, immunogens and antibodies
US4963355A (en) * 1986-06-23 1990-10-16 Igen, Inc. Production of antibody catalysts
US4792446A (en) * 1986-06-23 1988-12-20 Igen, Inc. Production of antibody catalysts
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US5079152A (en) 1987-05-28 1992-01-07 Scripps Clinic And Research Foundation Antibody combining sites that exhibit stereoselective synthase activity, and methods using the same
US5187086A (en) * 1990-01-26 1993-02-16 Scripps Clinic And Research Foundation Molecules with antibody combining sites that catalyze hydrolysis reactions through use of a charged hapten
US5463028A (en) 1992-04-03 1995-10-31 The Trustees Of Columbia University In The City Of New York Reagents for generating a polyclonal hydrolytic antibody response against cocaine and the monoclonal hydrolytic antibodies against cocaine derived through these reagents

Also Published As

Publication number Publication date
AU4101293A (en) 1993-11-08
US6566084B1 (en) 2003-05-20
US5990285A (en) 1999-11-23
US6184013B1 (en) 2001-02-06
ATE258933T1 (de) 2004-02-15
EP0642507B1 (de) 2004-02-04
US5977314A (en) 1999-11-02
CA2132982A1 (en) 1993-10-14
EP0642507A1 (de) 1995-03-15
WO1993020076A1 (en) 1993-10-14
US5463028A (en) 1995-10-31
CA2132982C (en) 2003-07-29
AU678161B2 (en) 1997-05-22
JPH07508712A (ja) 1995-09-28
EP0642507A4 (en) 1995-03-29

Similar Documents

Publication Publication Date Title
DE69333412D1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
DE3681466D1 (de) Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten.
ATE54154T1 (de) Retro-inverse analoga des bradykininpotentialisierenden peptids bpp-5a und verfahren zu ihrer herstellung.
DK0751992T3 (da) Karendotelvækstfaktor 2
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
FI905956A0 (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
DE4392749T1 (de) Gereinigte Formen von Dnase
ATE119040T1 (de) Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten.
DE3877529T2 (de) Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
ATE433959T1 (de) Analoge von kokain
ATE98376T1 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
AU6567086A (en) Compositions and methods for the treatment of bleeding disorders
ATA309588A (de) Neue kristallform von ciclosporin, verfahren zu ihrer herstellung, diese kristallform enthaltende pharmazeutische zusammensetzung und verwendung dieser kristallform
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
ATE157879T1 (de) Transformierte erythrozyten, verfahren zu deren herstellung, und ihre verwendung in pharmazeutischen zusammensetzungen
DE69122364T2 (de) Verwendung von (S)-Isofluran und (S)-Desfluran zur Anästhesie sowie entsprechende Arzneimittelzubereitungen
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
CA2010177A1 (en) Purified mite allergen
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
DE69402441T2 (de) Neue 17,20-Epoxyd Derivate von Pregnan, ihre Verwendung zur Herstellung von Cortison-Derivaten und Zwischenprodukte dafür
ATE164882T1 (de) Verfahren zur herstellung von aktivierten killer- monozyten und verfahren zur überprüfung ihrer tumoriziden aktivität
DE59409413D1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
ATE121726T1 (de) Hydroquinonester von aminosäuren, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische oder kosmetische zusammensetzungen.

Legal Events

Date Code Title Description
8332 No legal effect for de